Pennsylvania is currently home to 3297 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
NCT06688396
Recruiting
This is a prospective, single-arm clinical trial in which participants with dilated cardiomyopathy will invite their first degree relatives to undergo mobile cardiac, electrocardiogram screening.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Dilated Cardiomyopathy, Heart Failure, Heart Disease
Register for Updates
Hypofractionated WPPT With HDR Boost
NCT06591819
Recruiting
This is a phase II study of ultrahypofractionated whole pelvis proton therapy with brachytherapy boost for patients with high risk or unfavorable intermediate risk prostate with elevated risk of lymph node involvement.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
NCT06557785
Recruiting
This is a multicenter, open-label, non-randomized, dose escalation, first-in-human (FIH) trial to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160. Both products are mRNA encapsulated in lipid nanoparticles (LNPs) (subsequently referred to as mRNA-LNPs). The primary hypotheses are: 1. the CH505M5 N197D mRNA-gp160 will expand CH235-like B cell precursors, 2. the CH505 TF mRNA-gp160 will boost CH235-like bnAb B cell precursors to acquire more functional m... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/28/2025
Locations: Penn Prevention (Site ID: 30310), Philadelphia, Pennsylvania
Conditions: HIV Infections
Register for Updates
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
NCT06271291
Recruiting
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Pancreatic Carcinoma
Register for Updates
SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST
NCT06208748
Recruiting
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Gastrointestinal Stromal Tumors, GIST
Register for Updates
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT04631744
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC or patients with liver metastases.
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/28/2025
Locations: University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania
Conditions: Prostate Cancer
Register for Updates
NIH R01 Friend to Friend With Coaching
NCT04164472
Recruiting
This study examines the effectiveness of the Friend to Friend (F2F) program when conducted by teachers and counselors with active coaching from the research team. The project involves 14 small group sessions for relationally aggressive girls and 8 classroom sessions. Students, teachers, counselors and parents at intervention and control schools fill out pre- and post- program questionnaires.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Aggression
Register for Updates
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT01851694
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institute, Pottstown, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Digital Incentive Spirometry Adherence
NCT06629454
Recruiting
This single-arm proof-of-concept research study aims to assess the effect of a digital incentive spirometer (IS) device and a companion mobile-based app on incentive spirometry adherence in patients post-surgery. The digital IS utilizes a sensor to measure inspiratory breaths, and these data are transmitted wirelessly to a secure cloud database. The spirometer and app include a patient reminder system, exercise gamification strategies, progress tracking, and additional features designed to promo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Penn Medicine Valley Forge, Berwyn, Pennsylvania
Conditions: Pulmonary Function, Incentive Spirometry, Patient Adherence, Lung Resection, Thoracic Surgery
Register for Updates
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
NCT06499896
Recruiting
Multiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients. While \~67% of patients respond to corticosteroids, 33% of patients require biologic therapy such as TNFα inhibitors (e.g. infliximab), integrin α4β7 inhibitors (e.g. vedolizumab), or JAK/STAT inhibitors (e.g. tofactinib). This study aims to determine that distinct pathobionts govern the development of irCAE and IMC; and tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Immune-mediated Colitis (IMC), Immune-related Dermatitis
Register for Updates